Insider · CIK 0001366074

Lappe Mark

CIK 0001366074 Name as filed on the most recent filing

Filed as Lappe Mark (39)

98 transaction lines · from 39 filings · filed 2007-11-02 to 2024-09-16 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

21 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2024-09-16 P, Open-market purchase Inhibrx Biosciences, Inc.INBX 223,324, acquired Open Form 4 filing 0002007919-24-000049
2024-09-12 P, Open-market purchase Inhibrx Biosciences, Inc.INBX 405,793, acquired Open Form 4 filing 0002007919-24-000049
2024-09-10 P, Open-market purchase Inhibrx Biosciences, Inc.INBX 129,115, acquired Open Form 4 filing 0002007919-24-000045
2024-09-09 P, Open-market purchase Inhibrx Biosciences, Inc.INBX 144,495, acquired Open Form 4 filing 0002007919-24-000045
2024-09-06 P, Open-market purchase Inhibrx Biosciences, Inc.INBX 397,540, acquired Open Form 4 filing 0002007919-24-000045
2024-09-03 P, Open-market purchase Inhibrx Biosciences, Inc.INBX 2 lines 316,263, acquired Open Form 4 filing 0001739614-24-000037
2024-08-30 P, Open-market purchase Inhibrx Biosciences, Inc.INBX 140,200, acquired Open Form 4 filing 0001739614-24-000037
2024-08-29 P, Open-market purchase Inhibrx Biosciences, Inc.INBX 140,300, acquired Open Form 4 filing 0001739614-24-000037
2024-08-21 P, Open-market purchase Inhibrx Biosciences, Inc.INBX 167,379, acquired Open Form 4 filing 0002007919-24-000038
2024-08-20 P, Open-market purchase Inhibrx Biosciences, Inc.INBX 350,903, acquired Open Form 4 filing 0002007919-24-000038
2023-02-28 S, Open-market sale Inhibrx, Inc.INBX 1,501, disposed Open Form 4 filing 0001739614-23-000014
2023-01-24 S, Open-market sale Inhibrx, Inc.INBX 2 lines 111,478, disposed Open Form 4 filing 0001739614-23-000010
2023-01-23 S, Open-market sale Inhibrx, Inc.INBX 549,364, disposed Open Form 4 filing 0001739614-23-000010
2022-12-19 S, Open-market sale Inhibrx, Inc.INBX 2 lines 664,443, disposed Open Form 4 filing 0001739614-22-000130
2022-11-17 S, Open-market sale Inhibrx, Inc.INBX 7 lines 724,910, disposed Open Form 4 filing 0001739614-22-000124
2022-10-17 S, Open-market sale Inhibrx, Inc.INBX 4 lines 769,443, disposed Open Form 4 filing 0001739614-22-000107
2011-03-16 S, Open-market sale Aeolus Pharmaceuticals, Inc.AOLS 2,317,622, disposed Open Form 4 filing 0001140361-11-017510
2011-03-15 S, Open-market sale Aeolus Pharmaceuticals, Inc.AOLS 146,858, disposed Open Form 4 filing 0001140361-11-017510
2011-02-16 S, Open-market sale Aeolus Pharmaceuticals, Inc.AOLS 55,872, disposed Open Form 4 filing 0001140361-11-010589
2011-02-15 S, Open-market sale Aeolus Pharmaceuticals, Inc.AOLS 6,650, disposed Open Form 4 filing 0001140361-11-010589
2009-12-21 S, Open-market sale Repros Therapeutics Inc.RPRX 50,202, disposed Open Form 4 filing 0001140361-09-029903
2009-12-18 S, Open-market sale Repros Therapeutics Inc.RPRX 20,280, disposed Open Form 4 filing 0001140361-09-029903
2009-12-17 S, Open-market sale Repros Therapeutics Inc.RPRX 35,220, disposed Open Form 4 filing 0001140361-09-029903
2009-12-15 S, Open-market sale Repros Therapeutics Inc.RPRX 121,739, disposed Open Form 4 filing 0001140361-09-029245
2009-12-14 S, Open-market sale Repros Therapeutics Inc.RPRX 54,452, disposed Open Form 4 filing 0001140361-09-029245
2009-12-11 S, Open-market sale Repros Therapeutics Inc.RPRX 88,044, disposed Open Form 4 filing 0001140361-09-029245
2009-12-02 S, Open-market sale Repros Therapeutics Inc.RPRX 182,273, disposed Open Form 4 filing 0001140361-09-027917
2009-12-01 S, Open-market sale Repros Therapeutics Inc.RPRX 92,800, disposed Open Form 4 filing 0001140361-09-027917
2009-11-30 S, Open-market sale Repros Therapeutics Inc.RPRX 105,480, disposed Open Form 4 filing 0001140361-09-027917
2009-11-23 S, Open-market sale Repros Therapeutics Inc.RPRX 159,195, disposed Open Form 4 filing 0001140361-09-027215
2009-11-20 S, Open-market sale Repros Therapeutics Inc.RPRX 151,984, disposed Open Form 4 filing 0001140361-09-027215
2009-11-19 S, Open-market sale Repros Therapeutics Inc.RPRX 160,222, disposed Open Form 4 filing 0001140361-09-027215
2008-10-31 P, Open-market purchase Repros Therapeutics Inc.RPRX 87,688, acquired Open Form 4 filing 0001181431-08-059701
2008-10-31 P, Open-market purchase Repros Therapeutics Inc.RPRX 87,688, acquired Open Form 4 filing 0001104659-08-067952
2008-10-29 P, Open-market purchase Repros Therapeutics Inc.RPRX 170,068, acquired Open Form 4 filing 0001181431-08-059021
2008-10-29 P, Open-market purchase Repros Therapeutics Inc.RPRX 170,068, acquired Open Form 4 filing 0001104659-08-067039
2008-10-28 P, Open-market purchase Repros Therapeutics Inc.RPRX 67,958, acquired Open Form 4 filing 0001181431-08-059021
2008-10-28 P, Open-market purchase Repros Therapeutics Inc.RPRX 67,958, acquired Open Form 4 filing 0001104659-08-067039

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 21
  • Open-market sale 0
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Lappe Mark, insider transactions. Retrieved 2026-08-26 from https://ebomi.com/insider/0001366074

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.